ACA
ITOS

Avoro Capital Advisors’s iTeos Therapeutics ITOS Stock Holding History

Avoro Capital Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-460,000
Closed -$15.6M – 49
2020
Q4 		$15.6M Hold
460,000
– – 0.27% 34
2020
Q3 		$11.3M Buy
+460,000
New +$12.4M 0.16% 42

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Avoro Capital Advisors's ITOS Position: Q1 2021 in Review

Avoro Capital Advisors sold out of iTeos Therapeutics (ITOS) in Q1 2021, closing a stake of 460,000 shares — an estimated $15.6M sold.

Avoro Capital Advisors first reported a position in ITOS in Q3 2020 and held it in 2 quarters. The position peaked at $15.6M in Q4 2020. 81 funds tracked by Wall St. Rank hold ITOS as of Q1 2021.

  • Avoro Capital Advisors reported no remaining iTeos Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Avoro Capital Advisors sold 460,000 iTeos Therapeutics shares in Q1 2021, an estimated $15.6M.
  • Avoro Capital Advisors first reported a position in iTeos Therapeutics in Q3 2020 and held it in 2 quarters.
  • Avoro Capital Advisors's iTeos Therapeutics position peaked at $15.6M in Q4 2020.
  • 81 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2021.

Based on Avoro Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.